



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: JWH-210

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled
Not Controlled

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance is an efficient cannabinoid receptor agonist and therefore is included under item 1 of Schedule II to the CDSA.

Prepared by: Evelyn Soo Date: Nov 16th 2010

Verified by: Marianne Tang Date: _____

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: "third party information removed as per agreement with applicant"

Drug Status Report


Drug: JWH-210

Drug Name Status: JWH-210 is the common name

Chemical Name: (1-Hexyl-1H-indol-3-yl)-1-naphthalenylmethanone

Other Names: 1-Butyl-3-(4-ethyl-naphthoyl)indole

Chemical structure:



Molecular Formula: C₂₆H₂₇NO

Pharmacological class / Application: Synthetic cannabinoid

CAS-RN: 824959-81-1

International status:

US: JWH-210 is not currently listed in the schedules to US Controlled Substances Act and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: JWH-210 is not currently listed in the Schedules to the CDSA. The substance has been reported in the scientific literature to display very strong affinity towards the cannabinoid CB₁ receptor¹ and unpublished data from *in vitro* GTPγS assays have shown JWH-

¹Huffman, JW. (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB₁ and CB₂ receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB receptor agonists, *Bioorg. Med. Chem.* **13**:89-112.

210 to be a potent, efficacious CB₁ cannabinoid receptor agonist².

Cannabinoid receptor agonists have been declared included under item 1 of Schedule II to the CDSA while cannabinoid receptor antagonists have been declared excluded from item 1 of Schedule II. Considering that JWH-210 is a potent and efficient cannabinoid receptor agonist, it must be included under item 1 of Schedule II to the CDSA.

Recommendation: JWH-210 is included under item 1 of Schedule II to the CDSA and is a controlled substance.

Date: 15 November 2010

²Personal communication with Prof J Huffman, see email